Lexeo Therapeutics said discussions with the US FDA have positioned its LX‑2006 gene therapy for Friedreich ataxia cardiomyopathy on an accelerated approval pathway if pooled data from ongoing Phase I/II studies can provide persuasive efficacy and safety evidence. LX‑2006 is an intravenous, one‑time therapy aimed at restoring cardiac and neurologic function in a progressive degenerative disorder. Regulatory feedback framed pooling of datasets and use of surrogate endpoints as potential routes to an earlier biologics license application. Lexeo reported interim improvements in cardiac and neurologic measures from ongoing cohorts, and the stock reacted positively to FDA openness. The agency’s willingness to discuss accelerated pathways underscores continued regulatory flexibility for gene therapies addressing severe, unmet rare‑disease indications.